Arbutus Biopharma
ABUS
51 hedge funds and large institutions have $173M invested in Arbutus Biopharma in 2017 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 21 increasing their positions, 13 reducing their positions, and 13 closing their positions.
2,880% more call options, than puts
Call options by funds: $149K | Put options by funds: $5K
62% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 13
2.15% more ownership
Funds ownership: 60% → 62.15% (+2.1%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less funds holding
Funds holding: 53 → 51 (-2)
15% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 13
17% less capital invested
Capital invested by funds: $207M → $173M (-$34.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.35M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$1.65M |
| 3 |
Renaissance Technologies
New York
|
+$1.42M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$1.27M |
| 5 |
Morgan Stanley
New York
|
+$1.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$3.21M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.39M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$1.09M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$775K |
| 5 |
RI
RTW Investments
New York
|
-$672K |
ABUS Hedge Fund Activity: Q4 2017 in Review
51 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q4 2017, worth a combined $173M — down 17% from $207M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ABUS and 11 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 21 added.
The largest buyer was BlackRock, adding an estimated $4.35M. The largest seller was D.E. Shaw & Co, cutting an estimated $3.21M.
- 51 institutional investors held Arbutus Biopharma (ABUS) as of Q4 2017, down from 53 in Q3 2017.
- Funds reported $173M of Arbutus Biopharma stock for Q4 2017, down 17% quarter-over-quarter.
- 11 funds opened new Arbutus Biopharma positions in Q4 2017 and 13 closed out, a net change of -2 holders.
- The largest Arbutus Biopharma buyer in Q4 2017 was BlackRock, an estimated $4.35M added.
- The largest Arbutus Biopharma seller in Q4 2017 was D.E. Shaw & Co, an estimated $3.21M sold.
Based on aggregated 13F filings for Q4 2017.